Atypical antipsychotics and weight gain - A systematic review

Acta Psychiatrica Scandinavica

Volumn 101, Issue 6, 2000, Pages 416-432

  Taylor, David M ^a   McAskill, R ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amisulpride; Clozapine; Olanzapine; Quetiapine; Risperidone; Sertindole; Weight gain; Ziprasidone; Zotepine

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

APPETITE; BODY MASS; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; DIBENZOTHIEPINS; HUMANS; IMIDAZOLES; INDOLES; PIPERAZINES; PIRENZEPINE; RISPERIDONE; SULPIRIDE; THIAZOLES; WEIGHT GAIN;

EID: 0034121256     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.101006416.x     Document Type: Review

References (94)

1. 1. FOREYT J, GOODRICK K. The ultimate triumph of obesity. Lancet 1995;346:34-35.
2. 2. KALUCY RS. Drug-induced weight gain. Drugs 1980;19: 268-278.
3. 3. PIJL H, MEINDERS AE. Bodyweight change as an adverse effect of drug treatment. Drug Safety 1996;14:329-342.
4. 4. ACKERMAN S, NOLAN LJ. Bodyweight gain induced by psychotropic drugs: incidence, mechanisms and management. CNS Drugs 1998;9:135-151.
5. 5. PAYKEL EC, MUELTER PS, DE LA VERGNE PM. Drugs causing weight gain. Br J Psychiatry 1973;123:501-507.
6. 6. STANTON JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472.
7. 7. UMBRICHT D, KANE JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996;22:475-483.
8. 8. PARADA MA, HERNANDEZ L, PAEZ X et al. Mechanism of the body weight increase induced by systemic sulpiride. Pharmacol Biochem Behav 1989;33:45-50.
9. 2 receptor antagonist sulpiride. Exp Clin Endoc 1990;96:25-29.
10. 10. LOO H, POIRIER-LITTRE MF, THERON M et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1990;170: 18-22.
11. 11. BECH P, FLEUROT O, TURJANSKI S. Amisulpride versus risperidone in the treatment of acute schizophrenia. Poster presented at Biological Psychiatry Conference. Nice, France. 23-26 June 1997.
12. 12. PUECH A, FLEUROT O, REIN W et al. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr Scand 1998;98:65-72.
13. 13. COLONNA L, TURJANSKI S, DONDEY-NOUVEL L. Amisulpride long-term safety. Poster presented at 9th Congress of Association of European Psychiatrists, Copenhagen, Denmark, 20-24 September 1998.
14. 14. REIN W, TURJANSKI S, FAVENNEC-MEIDINGER C. Amisulpride, an atypical antipsychotic safety profile. Poster presented at Xth WPA Congress, Madrid, Spain, 23-28 August 1996.
15. 15. SIMPSON GM, VARGA E. Clozapine: a new and unusual antipsychotic agent. Psychopharmacol Bull 1975;11:14-15.
16. 16. JUUL POVLSEN U, NORING U, FOG R et al. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
17. 17. LIEBERMAN JA, KANE JM, JOHNS CA. Clozapine: guidelines for clinical management. J Clin Psych 1989;50:329-338.
18. 18. LEPPIG M, BOSCH B, NABER D et al. Clozapine in the treatment of 121 out-patients. Psychopharmacology 1989;99:S77-S79.
19. 19. GERLACH J, JØRGENSEN EO, PEACOCK L. Long-term experience with clozapine in Denmark: research and clinical practice. Psychopharmacology 1989;99:S92-S96.
20. 20. NABER D, LEPPIG M, GROHMANN R et al. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia a retrospective study of 387 patients. Psychopharmacology 1989;99:73-76.
21. 21. SCHMAUSS M, WOLFF R, ERFURTH A et al. Tolerability of long term clozapine treatment. Psychopharmacology 1989;99: S105-S108.
22. 22. COHEN S, CHILES J, MACNAUGHTON A. Weight gain associated with clozapine. Am J Psychiatry 1990;147:503-504.
23. 23. CARSON WH, FORBES RA. Letter. Am J Psychiatry 1990; 147:1694.
24. 24. LEADBETTER RA, VIEWEG V. Clozapine-induced weight gain [Letter]. Am J Psychiatry 1990;147:1693-1694.
25. 25. LEADBETTER R, SHUTTY M, PAVALON D et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
26. 26. LAMBERTI JS, BELLNIER T, SCHWARZKOPF SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-690.
27. 27. WIEBE EJ. Weight gain with clozapine treatment. Can J Psychiatry 1993;38:70.
28. 28. UMBRICHT DSG, POLLACK S, KANE JM. Clozapine and weight gain. J Clin Psychiatry 1994;55 (Suppl. B):157-160.
29. 29. HEIMBERG C, GALLACHER F, GUR RC et al. Diet and gender moderate clozapine-related weight gain. Hum Psychopharmacol 1995;10:367-371.
30. 30. JOHN JP, CHENGAPPA KNR, BAKER RW et al. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995;7: 119-125.
31. 31. JALENQUES I, TAUVERON I, ALBUISSON E et al. Weight gain as a predictor of long term clozapine efficacy. Clin Drug Invest 1996;12:16-25.
32. 32. BRIFFA D. MEEHAN T. Weight changes during clozapine treatment. Aust NZ J Psychiatry 1998;32:718-721.
33. 33. HUMMER M, KEMMLER G, KURZ M et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5: 437-440.
34. 34. BUSTILLO JR, BUCHANAN RW, IRISH D et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-819.
35. 35. DANIEL DG, GOLDBERG TE, WEINBERGER DR et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419.
36. 36. BONDOLFI G, DUFOUR H, PATRIS M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155:499-504.
37. 37. HONG CJ, CHEN JY, CHIU HJ et al. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol 1997;12:123-130.
38. 38. KRAUS T, HAACK M, SCHULD A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-314.
39. 39. WETTERLING T, MÜBIGBRODT, HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19: 316-321.
40. 40. WIRSHING DA, WIRSHING WC, KYSAR L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.
41. 41. BRÖMEL T, BLUM WF, ZIEGLER A et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998;3:76-80.
42. 42. FRANKENBURG FR, ZANARINI MC, KANDO J et al. Clozapine and body mass change. Biol Psychiatry 1998;43:520-524.
43. 43. BEASLEY CM, TOLLEFSON GD, TRAN PV. Safety of olanzapine. J Clin Psychiatry 1997;58 (Suppl. 10):13-17.
44. 44. TOLLEFSON GD, BEASLEY CM, TRAN PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
45. 45. TRAN PV, HAMILTON SH, KUNTZ AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
46. 46. CONLEY RR, BRECHER M. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Poster presented at European College of Neuropsychopharmacology Annual Meeting, November 1998, Paris, France.
47. 47. OSSER D, NAJARIAN DI, BERMAN I. Olanzapine increases weight and triglycerides. Poster presented at 151st American Psy-chiatric Association Conference, Toronto, Canada, 1-4 June 1998.
48. 48. Eli Lilly and Company Ltd. Summary of product characteristics. 1996.
49. 49. POTENZA MN, HOLMES JP, KANES SJ et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
50. 50. GUPTA S, DRONEY T, AL-SAMARRAI S et al. Olanzapine: weight gain and therapeutic efficacy [Letter]. J Clin Psychopharmacol 1999;19:273-275.
51. 51. BORISON RL, ARVANITIS LA, MILLER BG et al. ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169.
52. 52. SMALL JG, HIRSCH SR, ARVANITIS LA et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997:54:549-557.
53. 53. ARVANITIS LA, MILLER BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42: 233-246.
54. 54. PEUSKENS J, LINK CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273.
55. 55. MARTIN A, KOENIG K, SCAHILL L et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9:99-107.
56. 56. MEATS P. Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract 1997;1:231-239.
57. 57. GUNASEKARA NS, SPENCER CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998;9:325-340.
58. 58. CLAUS A, BOLLEN J, DE CUYPER H et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
59. 59. HØYBERG OJ, FENSBO C, REMVIG J et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
60. 60. MARDER SR, MEIBACH RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
61. 61. LAMBROSO PJ, SCAHILL L, KING RA. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34:1147-1152.
62. 62. PEUSKENS J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726.
63. 63. EMSLEY RA, MCCREADIE R, LIVINGSTON M et al. Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study. Poster presented at American Psychiatric Association Annual Conference, June, Toronto, Canada 1998.
64. 64. OWENS DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55 (Suppl. 5): 29-35.
65. 65. GRANT S, FITTON A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253-273.
66. 66. BRECHER M, BURKS E. Long-term safety of risperidone: results of seven 1-year trials. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy, 4-7 August, 1996, Nashville, TN.
67. 67. PENN JV, MARTINI J, RADKA D. Weight gain associated with risperidone. J Clin Psychopharmacol 1996;16:259-260.
68. 68. CROCKFORD DN. Risperidone, weight gain, and bulimia nervosa. Can J Psychiatry 1997;42:326-327.
69. 69. HORRIGAN JP, SIKICH L. Diet and the atypical neuroleptics [Letter]. J Am Acad Child Adolesc Psychiatry 1998;37: 1126-1127.
70. 70. BRECHER M, GELLER W. Weight gain with risperidone. J Clin Psychopharmacol 1997;17:435-436.
71. 71. KELLY DL, CONLEY RR, LOVE RC et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998;8:151-159.
72. 72. ZBOROWSKI J, SCHMITZ P, STASER J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. Poster presented at 148th American Psychiatric Association Meeting, May, Miami, Florida 1995.
73. 73. VAN KAMMEN DP, MCEVOY JP, TARGUM SD et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124: 168-175.
74. 74. HALE A, VAN DER BURGHT M, WEHNERT A et al. A European dose range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. Poster presented at XIXth Collegium Internationale Neuro-Psychopharmacologicum Meeting, June, Melbourne, Australia, 1996.
75. 75. KRYSTAL J, D'SOUZA DC, HOLGATE KL et al. Sertindole: a multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life in stable schizophrenic patients. Poster presented at American College of Neuropsychopharmacology Annual Meeting, December, San Juan, Puerto Rico 1996.
76. 76. ZIMBROFF DL, KANE JM, TAMMINGA CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154: 782-791.
77. 77. VAN KAMMEN D, HOLGATE KL, SEBREE T. Two open-label, long-term safety studies of sertindole. Poster presented at 34th American College of Neuropsychopharmacology Meeting, December, Puerto Rico, 1995.
78. 78. TAMMINGA CA, MACK RJ, GRANNEMAN GR et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997;12 (Suppl. 1): S29-S35.
79. 79. DAVIS R, MARKHAM A. Ziprasidone. CNS Drugs 1997;8: 153-159.
80. 80. GOFF DC, POSEVER T, HERZ L et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
81. 81. ARATO M, O'CONNOR R, MELTZER H. The ziprasidone extended use in schizophrenia (ZEUS) study: a prospective, double-blind, placebo-controlled, 1-year clinical trial. Lancet, in press.
82. 82. KECK P, BUFFENSTEIN A, FERGUSON J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998:140:173-184.
83. 83. DANIEL DG, ZIMBROFF DL, POTKIN SG et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20:491-505.
84. 84. PETIT M, RANIWALLA J, TWEED J et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32:81-87.
85. 85. COOPER SJ, BUTLER A, TWEED J et al. Zotepine in the treatment of chronic schizophrenia. Poster presented at the 9th Congress of the Association of European Psychiatrists, Copenhagen, 20-24 September 1998.
86. 86. PALMGREN K, TWEED JA, WELCH CP et al. A multicentre naturalistic long term study of zotepine. Poster presented at XXIInd Congress Collegium Internationale Neuro-Pharmacologicum, Glasgow, Scotland 1998.
87. 87. PRAKASH A, LAMB HM. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998;9:153-175.
88. 88. MCMANUS RJ, WILSON S, DELANEY BC et al. Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. Br Med J 1998; 317:1562.
89. 89. MOHER D, PHAM B, JONES A et al. Does quality of randomised trials affect estimates of intervention eficacy reported in meta-analysis? Lancet 1998:352:609-613.
90. 90. BLAND M. An introduction to medical statistics, 2nd edn. Oxford: Oxford University Press, 1995.
91. 91. ALLISON DB, MENTORE JL, MOONSEONG H et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
92. 92. BAPITSTA T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999:100:3-16.
93. 93. PARFITT K (ed.) Martindale. The complete drug reference, 32nd edn. London: Pharmaceutical Press, 1999.
94. 94. DUKES MNG (ed.) Meyler's side effects of drugs, 12th edn. Amsterdam: Elsevier, 1992.